Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy

J. L. Speyer, U. Beller, N. Colombo, J. Sorich, J. C. Wernz, H. Hochster, M. Green, R. Porges, F. M. Muggia, R. Canetta, E. M. Beckman

Research output: Contribution to journalArticlepeer-review

73 Scopus citations


From August 1985 to November 1989 we conducted a trial of intraperitoneal (IP) carboplatin including a dose-escalation design in 25 women with advanced gynecologic malignancies. All had extensive prior therapy with cisplatin (median cumulative dose, 525 mg/m2). Carboplatin was administered IP in 2 L of 1.5% dextrose with a 4-hour dwell time every 4 weeks for six cyles at a starting dose of 200 mg/m2. Patients with reduced creatinine clearance (30 to 60 cc/min) were escalated more slowly than those with high (> 66 cc/min) clearance. Thrombocytopenia was dose-limiting and often more severe in patients with compromised renal function; there was no local drug toxicity. The median time of follow-up is 25 months. Complete responses (CRs) were documented in six of 23 assessable patients (26%) by repeat laparotomy, and an additional 11 patients (48%) had no disease evident by noninvasive restaging. Five of the CRs and six of the patients with no clinically evident disease have relapsed from 3 to 40 months after therapy. Six patients (26%) are alive and free of disease 8 to 47 (median, 20) months after therapy. IP carboplatin is effective against relapsed ovarian cancer, even after prior cisplatin therapy.

Original languageEnglish (US)
Pages (from-to)1335-1341
Number of pages7
JournalJournal of Clinical Oncology
Issue number8
StatePublished - 1990
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Intraperitoneal carboplatin: Favorable results in women with minimal residual ovarian cancer after cisplatin therapy'. Together they form a unique fingerprint.

Cite this